Akebia Therapeutics Inc (AKBA)
1.21
-0.12
(-9.02%)
USD |
NASDAQ |
May 10, 16:00
1.21
0.00 (0.00%)
After-Hours: 20:00
Akebia Therapeutics Research and Development Expense (TTM): 63.08M for Dec. 31, 2023
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 63.08M |
| September 30, 2023 | 85.31M |
| June 30, 2023 | 100.01M |
| March 31, 2023 | 105.84M |
| December 31, 2022 | 129.99M |
| September 30, 2022 | 127.44M |
| June 30, 2022 | 139.89M |
| March 31, 2022 | 151.07M |
| December 31, 2021 | 147.85M |
| September 30, 2021 | 155.87M |
| June 30, 2021 | 162.26M |
| March 31, 2021 | 177.86M |
| December 31, 2020 | 218.48M |
| September 30, 2020 | 261.32M |
| June 30, 2020 | 288.97M |
| March 31, 2020 | 321.85M |
| December 31, 2019 | 322.97M |
| September 30, 2019 | 329.61M |
| June 30, 2019 | 325.73M |
| March 31, 2019 | 311.95M |
| December 31, 2018 | 291.01M |
| Date | Value |
|---|---|
| September 30, 2018 | 272.34M |
| June 30, 2018 | 260.41M |
| March 31, 2018 | 232.25M |
| December 31, 2017 | 230.89M |
| September 30, 2017 | 195.95M |
| June 30, 2017 | 168.47M |
| March 31, 2017 | 155.60M |
| December 31, 2016 | 115.78M |
| September 30, 2016 | 96.59M |
| June 30, 2016 | 80.96M |
| March 31, 2016 | 56.59M |
| December 31, 2015 | 43.02M |
| September 30, 2015 | 33.71M |
| June 30, 2015 | 24.75M |
| March 31, 2015 | 23.77M |
| December 31, 2014 | 23.26M |
| September 30, 2014 | 19.64M |
| June 30, 2014 | 16.23M |
| March 31, 2014 | 13.16M |
| December 31, 2013 | 8.902M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
63.08M
Minimum
Dec 2023
329.61M
Maximum
Sep 2019
190.28M
Average
155.87M
Median
Sep 2021
Research and Development Expense (TTM) Benchmarks
| Ocugen Inc | 39.57M |
| Aquestive Therapeutics Inc | 15.49M |
| Amicus Therapeutics Inc | 139.21M |
| Insmed Inc | 571.01M |
| InfuSystems Holdings Inc | -- |